Latest Conference Articles

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.

These data from RAD 2025 highlight upadacitinib’s efficacy in the phase 3 Measure Up 1 and 2 studies for older adults with atopic dermatitis.

At SLEEP 2025, Malhotra emphasized the need for weight loss to resolve obesity hypoventilation syndrome and highlighted limitations of current therapies.

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.

This Q&A interview at RAD 2025 features a discussion about a talk titled ‘Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis.’

At SLEEP 2025, HCPLive spoke to Strollo about the phase 3 SynAIRgy trial which evaluated AD109, a first-in-class, once-daily oral neuromuscular modulator, for OSA.

At SLEEP 2025, Cassiere discussed how pulse oximetry inaccuracies among patients with darker skin tones may lead to underdiagnosis or misclassification of sleep apnea severity.

At SLEEP 2025, Lillis discussed how wearable data revealed disruptions in sleep consolidation up to 13 weeks postpartum despite total sleep duration nearing pre-pregnancy levels.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

By week 2 postpartum, sleep duration rebounds, but fragmented sleep persists through week 13, Teresa Lillis, PhD, presented at SLEEP 2025.

At SLEEP 2025, Walia discussed findings showing Hispanic individuals may experience more severe cases of sleep disordered breathing compared to the non-Hispanic group.

At SLEEP 2025, Bruce Corser, MD, discussed promising open-label data on pitolisant’s impact on idiopathic hypersomnia symptoms with HCPLive.

At SLEEP 2025, Winkelman discussed the AASM’s updated guidelines urging clinicians to transition patients with RLS off dopamine agonists due to augmentation risks.

At SLEEP 2025, Kancherla highlights diagnostic dilemmas, treatment gaps, and the need for pediatric criteria when managing obstructive sleep apnea in teens.

At SLEEP 2025, Kancherla emphasized the importance of using pediatric criteria to manage OSA in adolescents, warning that adult standards may overlook key developmental factors.

This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.

These data suggest that smoking history did not impact rates of malignancy, MACE, and VTE among those with atopic dermatitis treated with upadacitinib.

In this Q&A interview at RAD 2025, Tiffany Mayo, MD, highlights the biggest takeaways from her talk on complex cases in atopic dermatitis and hair loss.

Potentially the first successful CETP inhibitor, obicetrapib has shown positive trial results in reducing the risk of cardiovascular disease when combined with statins.

At SLEEP 2025, Axsome Therapeutics presented phase 3 ENCORE and SYMPHONY data showing AXS-12 reduced cataplexy attacks and improved daytime functioning in narcolepsy.